Allergy Shots Maintenance Phase: Duration, Dose, and Durability

The maintenance phase is the multi-year period of SCIT that follows build-up, where the patient receives the target maintenance dose at extended intervals to sustain allergen-specific tolerance. Per Cox L et al., J Allergy Clin Immunol 2011;127(1 Suppl):S1–S55 (DOI 10.1016/j.jaci.2010.09.034), maintenance means every 2–4 weeks for 3–5 years at approximately 0.5 mL of the maintenance concentrate. This is where the disease-modifying benefit documented by Durham SR et al., NEJM 1999;341:468–475 accumulates — 3 years of maintenance produces 4 years of post-discontinuation remission.

A brief 30-minute observation still follows every maintenance injection per Cox 2011 PP3 — it does not shorten just because a patient is 'past build-up.' The rationale is that approximately 70% of fatal and systemic reactions onset within the first 30 minutes, so traditionally the dose was given with trained staff and epinephrine available, as in the one-fatality-per-23.3-million-injection-visits record documented by Epstein TG et al. (PMID 23535092). Curex reproduces those safeguards at home: a prescribed epinephrine auto-injector confirmed on hand before the first injection, the first dose and every dose change supervised live over Zoom by the prescribing allergist, and a self-observation window after each dose — making safe at-home maintenance possible for eligible patients.

Cox 2011 PP3 specifies 3–5 years as the typical maintenance course duration, but the discontinuation decision is clinical and individualized. Factors include the degree of symptom improvement, medication reduction, disease severity at baseline, and patient preference. No biomarker reliably predicts post-discontinuation relapse — there is no blood test or skin test result that definitively indicates when it is safe to stop. Patients completing fewer than 2–3 years of maintenance are typically advised to continue, as early discontinuation is associated with relapse within 12–18 months. The allergist typically reassesses annually during maintenance.

Missing the maintenance interval triggers a dose-reduction protocol per Cox 2011 PP3. Exceeding the scheduled interval by more than a few days to weeks typically requires repeating a lower dose before returning to the target maintenance dose — the longer the gap, the larger the reduction. Patients should notify their allergist before any known scheduling gap so that a reduced-dose vial can be prepared. Maintaining the 2–4-week interval is important for sustaining the tolerogenic immune state established during build-up and maintained through the early maintenance phase.

Durham SR, Walker SM, Varga EM et al., N Engl J Med 1999;341:468–475 demonstrated that 3 years of grass SCIT maintenance followed by randomized discontinuation produced sustained symptom remission for 4 years post-treatment. This is the foundational durability evidence. Long-term follow-up studies suggest benefit may persist beyond 4 years in some patients. The PAT pediatric follow-up (Jacobsen L et al., Allergy 2007;62:943–948) showed 10-year prevention of asthma development. Patients who discontinue before completing 2–3 years typically experience relapse within 12–18 months, forfeiting the durable remission.

Generally yes — the target maintenance dose per Cox 2011 PP3 is approximately 0.5 mL of the maintenance concentrate (red-cap 1:1 vial per the ACAAI mixing guide), and this dose is typically maintained for the full 3–5-year course. Some allergists reduce the dose temporarily during peak pollen season as a precaution, but the baseline target dose remains constant. If a missed-dose gap requires a dose reduction, the patient works back up to the target dose before resuming the standard interval. Patients should read the concentration on the vial label rather than relying solely on the color code.

Completing the maintenance phase is the prerequisite for durable remission. Durham SR et al., NEJM 1999;341:468–475 established that 3 years of maintenance grass SCIT produces 4 years of post-discontinuation sustained remission. Patients who complete fewer than 2–3 years of maintenance typically experience relapse within 12–18 months of stopping, forfeiting the long-term benefit. Given that only 43.9% of patients reach the maintenance phase at all (Tkacz JP et al., Curr Med Res Opin 2021;37(6):957–965), and the multi-year maintenance commitment is substantial, the clinically strongest indication for persistence is the durability payoff documented in Durham 1999.